Pharsight

Oxycontin generic

Oxycontin, an opioid utilized for managing severe pain, is owned by Purdue Pharma Lp. The tablet, which has been available since 05 April, 2010, is an extended-release oral dosage form. The active ingredient in Oxycontin is oxycodone hydrochloride. Purdue Pharma Lp holds a total of 21 patents for Oxycontin, out of which 5 have already expired.

When will Oxycontin generic be available?

The generic version of Oxycontin is anticipated to be released after 29 March, 2030. This is because the last patent of Oxycontin, US8894987 titled 'Tamper resistant dosage forms', will only expire in 2030.

Oxycontin uses

Oxycontin is primarily used for the management of severe pain that requires daily, around-the-clock, long-term opioid treatment. It is often prescribed when alternative treatment options are inadequate. The effectiveness of Oxycontin can be attributed to its active ingredient, oxycodone hydrochloride, which works by changing the way the brain and nervous system respond to pain.

Oxycontin patent expiration

Of the 21 patents of Oxycontin held by Purdue Pharma Lp, 5 have already expired. The remaining patents will expire at various dates, with the last one, US8894987, expiring on 29 March, 2030. Once this patent has expired, the door will be open for the release of Oxycontin generic. Below is the detail of the patent:

EPO Oppostions filed on Oxycontin

Litigations filed on Oxycontin

Oxycontin dosage

Want to ask something?